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Summary
Objective: In vitromodels of chondrogenesis often depart fromchondrocytes harvested from less-affected areas of osteoarthritic joints. However,
there are indications that these chondrocytes are phenotypically different from chondrocytes from healthy joints and thus might differ in their ca-
pacity to generate hyaline cartilage. The goal of this studywas to compare the chondrogenic capacity of chondrocytes fromhealthy andOA joints.
Design: Chondrocytes isolated from nine healthy and nine OA knee joints were expanded in monolayer for two passages. Chondrocytes from
passages 1 and 2 were analyzed for expression of (de)differentiation and hypertrophy markers and were seeded at passage 2 on collagen-
coated ﬁlters for redifferentiation culture to study cartilage matrix formation.
Results: The collagen II/I mRNA ratio, reﬂecting differentiation, decreased from passage 1 to 2 in both chondrocytes from OA joints and chon-
drocytes from healthy joints (P< 0.05), without a signiﬁcant difference between the two donor types. At passage 1, levels of the cartilage tran-
scription factors Sox-5, Sox-6 and Sox-9 appeared to be higher in chondrocytes from OA joints (n.s.), but this was not seen at passage 2.
However, a clear difference was observed in collagen type X expression, which was high in chondrocytes from OA joints at both passages,
while undetectable in chondrocytes from healthy joints (P< 0.01). Tissue generated by chondrocytes from healthy joints redifferentiated for 28
days, showed a signiﬁcantly better morphology, as assessed by histological scoring (P< 0.01) and higher proteoglycan content (P< 0.05),
compared to chondrocytes from OA joints. Matrix turnover parameters, i.e., proteoglycan synthesis and degradation rate, were not signiﬁcantly
affected by donor tissue origin.
Conclusions: These results suggest that clear differences between chondrocytes from healthy and OA joints exist and that these are not com-
pletely abolished during the process of de- and redifferentiation. Therefore, in vitro cartilage regeneration models, which use chondrocytes
from OA joints, should be interpreted with care.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Autologous chondrocyte transplantation (ACT) has been
shown to be a promising technique for the treatment of car-
tilage defects. However, the quality of the tissue synthe-
sized in vivo still varies greatly, ranging from hyaline
cartilage to ﬁbrocartilaginous and hypertrophic tissue1e3.
Hence, a great deal of research is being carried out to study
and optimize cartilage regeneration, both in vivo and in vitro.
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2005.56As in ACT, in vitro cartilage regeneration models depart
from chondrocytes isolated from cartilage biopsies and ex-
panded in monolayer. During this process, chondrocytes
dedifferentiate and start producing aspeciﬁc extracellular
matrix proteins, such as collagen type I4,5. In vitro rediffer-
entiation is subsequently achieved, usually by seeding the
dedifferentiated cells at high density in medium with appro-
priate factors. Frequently, chondrocytes used for in vitro re-
search are harvested from less-affected areas of
osteoarthritic joints, as this is a readily available source of
cells. However, it is not clear whether these chondrocytes
are actually phenotypically identical to chondrocytes from
healthy joints. Transformation to osteoarthritic tissue is not
very likely to involve sudden changes, but is more likely to
be a gradual and initially microscopically invisible process.
Although it may be argued that dedifferentiation, occurring
as a result of expansion of harvested chondrocytes, effaces
existing differences, leading to identical tissue compositions
upon regeneration, it has never been investigated whether
this is actually the case. Chondrocytes harvested from
‘‘healthy’’ areas of osteoarthritic joints may already display
characteristics of chondrocytes in osteoarthritic lesions.
These characteristics are an increased proteoglycan turn-
over rate, resulting from enhanced proteoglycan synthesis1
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type X collagen, and the expression of matrix degrading
proteases such as cathepsin B and matrix metalloprotei-
nase (MMP)-13. Moreover, chondrocytes from OA joints
display a shift towards the production of collagen type I at
the expense of collagen type II. As the chondrocyte pheno-
type, in particular the expression of collagen II and aggre-
can, is dependent on the expression of the transcription
factors L-Sox-5, Sox-6 and Sox-9, the diminished produc-
tion of cartilaginous matrix proteins by the OA chondrocyte
might be associated with decreased levels of these tran-
scription factors.
The aim of the current study was to investigate to what
extent chondrocytes harvested from OA joints display an al-
tered, more dedifferentiated or hypertrophic, phenotype af-
ter expansion, compared to chondrocytes from healthy
joints and to what extent this is associated with differences
in cartilage regeneration upon dedifferentiation in mono-
layer and redifferentiation in a previously described in vitro
model12.
Materials and methods
CHONDROCYTE ISOLATION AND EXPANSION
Articular cartilage was harvested from healthy and osteo-
arthritic joints. From healthy knee joints cartilage was har-
vested postmortem (within 24 h after death) from femoral
condyles of nine human donors, average age 50.3 years
(38e68), ﬁve males and four females. From osteoarthritic
knee joints, during joint replacement surgery, cartilage
was harvested from femoral condyles of nine human do-
nors, average age 65 years (57e73), three males and six
females. Only cartilage that macroscopically looked rela-
tively normal was used for this study, but cartilage biopsies
from OA donors were more yellowish and had a softer
texture compared to cartilage from healthy knee joints. No
ﬁbrous scar-like tissue was used. As all tissue was needed
for adequate culture volumes, no tissue could be stored
for histology. Therefore the morphological quality of the tis-
sue could not be determined. In a separate study, tissue
was harvested in an identical manner and an average mod-
iﬁed Mankin score of 5.3 2.8 points was observed
(0¼ normal, 11¼ complete degeneration13) (unpublished
results). Exclusion criteria were a clinical history of inﬂam-
matory or crystalline joint disorders and usage of corticoste-
roids (systemically or intra-articularly) within 1 month before
biopsy. The biopsies were transported in Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM) (Gibco, Paisly, UK) contain-
ing 4.5 mg/ml glucose, L-glutamine, 10% fetal bovine
serum (FBS) (Gibco), 1 nonessential amino acids (Sigma,
St Louis, USA), 10 mM N-(2-hydroxyethyl)piperazine-N 0-
[2-ethanesulfonic acid] (HEPES) buffer (Gibco), 100 U/ml
penicillin, 100 mg/ml streptomycin (Gibco), 0.2 mM L-ascorbic
acid (Sigma) and 0.4 mM proline (Sigma) at 4(C.
Within 12 h after biopsy, chondrocytes were isolated by
a 3-h 0.1% pronase (Roche, Mannheim, Germany) diges-
tion followed by an over-night 0.04% collagenase (Sigma)
digestion at 37(C. Undigested debris was removed using
a 100 mm cell strainer (Becton Dickson, Franklin Lakes,
USA). The cells were washed once in phosphate buffered
saline (PBS) and brought into suspension in expansion
medium consisting of DMEM (Gibco) containing 4.5 mg/ml
glucose, 10 mM HEPES buffer, 10% FBS, 100 U/ml penicil-
lin and 100 mg/ml streptomycin. Subsequently, the chondro-
cytes were seeded in monolayer at a cell density of
5000 cells/cm2 and cultured in expansion medium. Theexpansion medium was supplemented with 10 ng/ml basic
ﬁbroblast growth factor (bFGF) (R&D, Minneapolis, MN,
USA), except for the ﬁrst 3 days of culture. The cells were
cultured at 37(C and 5% CO2 for two passages. The culture
medium was renewed every 3 days. At conﬂuency the cells
were trypsinized using 0.25% trypsin/ethylenediaminetetra-
acetic acid (EDTA) (Gibco) and were replated. The viable
cells were counted using a Bu¨rker Tu¨rk hemacytometer af-
ter staining with Trypan Blue. These cell numbers were
used to calculate the number of population doublings
(PDs) that occurred during expansion and the amount of
cell suspension required for further expansion and/or redif-
ferentiation. Part of the cells was harvested for mRNA ex-
traction and ensuing polymerase chain reaction (PCR),
while the remainder was redifferentiated for 28 days to de-
termine the chondrogenic capacity.
REDIFFERENTIATION CULTURE
After the two passages, the cells were cultured in a previ-
ously published redifferentiation model in which the chon-
drocytes are seeded at a density of 1.6 106 cells/cm2
(720,000 cells/ﬁlter) on millicell ﬁlters (Millipore Co, Bedford,
MA, USA) that were precoated with collagen type II
(Sigma)12. The original model has been adapted by elimi-
nating serum, N-(2-hydroxyethyl)piperazine-N 0-[2-ethane-
sulfonic acid] and b-glycerolphosphate, in order not to
direct the redifferentiating chondrocytes towards a hyper-
trophic pathway. Instead, the cells were cultured in a
redifferentiation medium consisting of DMEM (Gibco) sup-
plemented with 10% human serum albumin (Equitech-Bio,
Kerrville, TX, USA), 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 0.4 mM ascorbic acid, 1 ITSx (Gibco) and 5 ng/ml
TGF-b2 (R&D). The cultures were incubated at 37(C in
5% CO2. The culture media were renewed every 3 days.
This culture model with above described adaptations has
been validated in a separate study (unpublished results).
HISTOLOGY
After 28 days of culture, samples were ﬁxed in 10% buff-
ered formalin for histological evaluation (Safranin O/Fast
green). Sections were cut at 5 mm and stained with Safranin
O/Fast Green. The histological quality of the tissue was an-
alyzed by four blinded observers using a scoring system
speciﬁcally designed to evaluate cartilage synthesized
in vitro (obtained through personal communication). This
scoring system will be further referred to as the ‘‘Bern
Score’’14. This scoring system evaluates uniformity and in-
tensity of Safranin O staining, the distance between cells,
the amount of matrix produced and cell morphology. Each
item can be given a maximum of 3 points, thus optimal tis-
sue quality scores 9 points.
IMMUNOHISTOCHEMISTRY
After 28 days of culture, samples were embedded in Tis-
sueTek O.C.T. compound (Sakura, Torrance, CA, USA),
cut at 5 mm, and stained immunohistochemically for colla-
gen type I and type II to assess the degree of redifferentia-
tion. For immunohistochemical staining, the sections were
incubated with monoclonal antibodies against collagen
type I and type II (1:1500 Omnilabo and 1:100 Developmen-
tal Studies Hybridoma Bank, respectively) for 1 h at room
temperature (RT). Subsequently the samples were incu-
bated with a biotinylated goat anti-mouse secondary
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(Liquid DABþ Substrate, DAKO, Glostrup, Denmark) was
used to obtain a signal in positive cells or matrix. Finally
the sections were counterstained with hematoxylin.
PROTEOGLYCAN SYNTHESIS
The proteoglycan synthesis rate was analyzed by a 35S-
incorporation assay after 9 days of culture in three samples
per donor. During 4 h the samples were incubated in the
presence of 4 mCi 35SO4
2 (Na2
35SO4, carrier-free; NEX-
041-H; Dupont) in 210 ml culture medium. Subsequently,
the samples were rinsed three times in 4(C PBS to stop
35S-incorporation. The samples were stored at 20(C until
further analysis. At analysis, the samples were digested in
12% papain (Sigma) buffer, 25 mg/ml in 50 mM phosphate
buffer, pH 6.5, containing 2 mM N-acetylcysteine and
2 mM Na2EDTA at 65(C for 2 h. Aliquots of the digest
were used to measure the DNA content. Sterile water was
added to the remaining sample to obtain a volume of
400 ml. Proteoglycans were precipitated using 290 mM
hexadecylpyridinium-chloride (Sigma). The precipitate was
dissolved in 3 M NaCl and was used to measure 35S-incor-
poration. 35S-incorporation was normalized to the DNA con-
tent in the sample.
DNA CONTENT
To determine DNA content after 9 and 28 days of culture,
the samples were digested as described above and
analyzed spectrophotometrically on the Cytoﬂuor 4000 us-
ing HOECHST 33258 labeling15. Calf thymus DNA was
used as a reference. All measurements were done in
triplicate.
PROTEOGLYCAN RELEASE
Proteoglycan release rate was analyzed in three samples
per donor, using a previously described Alcian Blue assay,
which measures glycosaminoglycans (GAGs) released in
the culture medium16. To this end, the culture medium
was collected every 3 days when the medium was changed.
It was stored at 20(C until further analysis. The GAGs
were precipitated from the medium and stained with an Al-
cian Blue dye solution (Alcian Blue: 8GX, Sigma, saturated
in 0.1 M sodium acetate buffer, pH 6.2, containing 0.3 M
MgCl2) for 30 min at 37(C. The blue staining of the medium
was quantiﬁed spectrophotometrically by the change in ab-
sorbance at 620 nm. Values were normalized per donor to
the total amount of GAG synthesized during the whole cul-
ture period (sum of total GAG content at day 28 and the to-
tal amount of GAGs released during the whole culture
period).
TISSUE PROTEOGLYCAN CONTENT
As a parameter of matrix synthesized and contained
within the tissue, the proteoglycan content after 28 days
of culture was determined in three samples per donor using
an Alcian Blue precipitation assay on tissue digests as de-
scribed previously11. To this end, the samples were di-
gested in 12% papain buffer as described above.
Separate aliquots of the digest were used to determine
DNA content and GAG concentration present in the sam-
ples was measured using the above described Alcian
Blue assay.RNA ISOLATION AND cDNA SYNTHESIS
Cartilage explants from OA human knee joints were used
as a control for normalization of gene-expression levels in
experimental samples. The cartilage biopsies were snap-
frozen in liquid nitrogen and crushed using a pestle and
mortar. The ground cartilage was suspended in RNeasy ly-
sis buffer (RLT buffer, RNeasy Mini Kit, Qiagen, Hilden,
Germany). The suspension was homogenized using a sy-
ringe and a needle. Subsequently the samples were centri-
fuged for 10 min at 300 g and the supernatant was used
for total RNA extraction. Completion of total RNA extraction
was done by using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol17.
Total RNA was extracted from cells cultured in monolayer
after the ﬁrst and second passages. At conﬂuency, the cells
were trypsinized in 0.25% trypsin/EDTA. Subsequently the
cells were washed in PBS and resuspended in expansion
medium. Cells (5 105) were spun at 300 g at RT to
form cell pellets that were stored at 80(C until used for
further analysis. From these pellets, total RNA was ex-
tracted using the RNeasy Mini Kit (Qiagen) according to
the manufacturer’s protocol. RNA concentration was mea-
sured spectrophotometrically at 260 nm and sufﬁcient
RNA purity was assumed if the 260/280 nm ratio was be-
tween 1.6 and 2.0.
Before cDNA synthesis, all samples were DNase treated.
Subsequently, 750 ng of RNA was reverse transcribed us-
ing the iScript cDNA synthesis kit (BioRad, USA) according
to the manufacturer’s protocol and afterward diluted ﬁve
times in diethylpyrocarbonate (DEPC)-treated water.
SEMIQUANTITATIVE REAL TIME REVERSE TRANSCRIPTASE
POLYMERASE CHAIN REACTION (RT-PCR) ANALYSIS
L-Sox-5, Sox-6, Sox-9, MMP-13 and cathepsin B mRNA
levels were determined by semiquantitative real time RT-
PCR using an SYBR Green assay on the MyiQ thermal cy-
cler (BioRad, USA). Human L-Sox-5, Sox-6 and Sox-9
primer sequences were kindly provided by Dr A. D. Mur-
doch (Wellcome Trust Centre for Cell Matrix Research, Uni-
versity of Manchester, UK). MMP-13 and cathepsin B
primers were designed using primer express software
(Table I). The speciﬁcity of all primer sets was checked by
BLASTN searches. The PCR reaction mix contained
12.5 ml iQ SYBR Green Supermix (BioRad, USA), 1 ml
FWD primer, 1 ml RVS primer, 5.5 ml DEPC-treated water
and 5 ml cDNA. Product length control was done by gel
electrophoresis and melt curve analysis. Expression levels
were normalized to endogenous glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) expression levels and
were calculated using the method according to Pfafﬂ18 to
correct for the efﬁciency of the reaction. With this method
relative expression is calculated only from efﬁciencies and
crossing point deviation of an unknown sample vs a control
for which we used mRNA of OA cartilage.
Collagen type I, II, X and aggrecan mRNA levels were de-
termined by semiquantitative real time RT-PCR using
a Taqman assay on the ABI prism 7900HT sequence detec-
tion system. (Primers and probes generously provided by
Dr H. Jahr, Department of Orthopaedics, Rotterdam, The
Netherlands.) The PCR mix contained 5 ml cDNA, 12.5 ml
2 universal mastermix (Applied Biosystems) and 1.0 ml
of collagen type I, and II and X primer, 0.5 ml of aggrecan
primer and 1.0 ml of each probe (250 nM) and for GAPDH
we used 1.25 ml primer/probe mix (Applied Biosystems)
and 5 ml of cDNA in a 25 ml reaction volume. The expression
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Primers sequences used for semiquantitative real time PCR using the SYBR Green assay. mRNA levels were normalized to GAPDH mRNA
levels. Collagen type I, II, X and Aggrecan mRNA levels were semiquantified using a Taqman real time PCR assay and normalized to GAPDH
Primer sequences Amplicon length (bp) Concentration (nM) Annealing temperature ((C)
Sox-9
FWD 50 GAC TTC CGC GAC GTG GAC 30 98 300 60
RVS 50 GTT GGG CGG CAG GTA CTG 30 300
L-Sox-5
FWD 50 ATC CCA ACT ACC ATG GCA GCT 30 61 300 60
RVS 50 TGC AGT TGG AGT GGG CCT A 30 300
Sox-6
FWD 50 GCA GTG ATC AAC ATG TGG CCT 30 119 300 60
RVS 50 CGC TGT CCC AGT CAG CAT CT 30 300
MMP-13
FWD 50 AAA TTA TGG AGG AGA TGC CCA TT 30 125 200 64
RVS 50 TCC TTG GAG TGG TCA AGA CCT AA 30 200
Cathepsin B
FWD 50 TGT GTA TTC GAA CTT CCT GCT 30 112 200 64
RVS 50 GTG TGC CAT TCT CCA CTC C 30 200
Collagen type I
FWD 50 CAG CCG CTT CAC CTA CAG C 30 83 300 60
RVS 50 TTT TGT ATT CAA TCA CTG TCT TGC C 30 300
Probe 50 CCG GTG TGA CTC GTG CAG CCA TC 30 100
Collagen type II
FWD 50 GGC AAT AGC AGG TTC ACG TAC A 30 79 900 60
RVS 50 CGA TAA CAG TCT TGC CCC ACT T 30 900
Probe 50 CCG GTA TGT TTC GTG CAG CCA TCC T 30 200
Collagen type X
FWD 50 CAA GGC ACC ATC TCC AGG AA 30 70 900 60
RVS 50 AAA GGG TAT TTG TGG CAG CAT ATT 30 900
Probe 50 TCC AGC ACG CAG AAT CCA TCT GA 30 200
Aggrecan
FWD 50 TCG AGG ACA GCG AGG CC 30 85 900 60
RVS 50 TCG AGG GTG TAG CGT GTA GAG A 30 900
Probe 50 ATG GAA CAC GAT GCC TTT CAC CAC GA 30 200
GAPDH
FWD 50 AGA AGG CTG GGG CTG ATT T 30 135 300 60
RVS 50 GAG GCA TTG CTG ATG ATC TTG 30 300levels were normalized to endogenous GAPDH expression
levels and were calculated using the 2DDCt formula (ABI
Prism 7700 sequence Detection System User bulletin #2).
Since collagen type II is one of the typical markers of differ-
entiated chondrocytes in hyaline cartilage and collagen type
I is mainly synthesized in dedifferentiated chondrocytes, we
deﬁned the ratios of mRNA levels CII/CI as ‘‘differentiation
index’’. Collagen and aggrecan primers and probe se-
quences are previously published by Martin and Mandl19,20.
GAPDH primer and probe endogenous control mix is com-
mercially available (Applied Biosystems). Primer se-
quences and concentrations can be found in Table I.
STATISTICAL ANALYSIS
For postexpansion mRNA levels, the effect of donor type
and passage number was analyzed by multiple factor anal-
ysis of variance (factorial ANOVA) using the general linear
model. If interaction between variables was observed, the
mean values of the treatment groups were compared using
Tukey’s post hoc test. For postredifferentiation analysis
methods, e.g., Bern Score, 35S-sulphate incorporation,
GAG release etc., analysis of the data of the various assays
was done using Student’s t tests after conﬁrming equal var-
iances of the data. If the data were right skewed instead ofnormally distributed, a log-transformation was applied be-
fore analysis. In cases of unequal variances, the data
were analyzed using a ManneWhitneyeWilcoxon rank
sum test (signiﬁcance level, P 0.05). Statistical calcula-
tions were done with JMP (Cary, NC, USA), version 5.1,
statistical analysis software.
Results
POPULATION DOUBLING
During monolayer culture, no obvious differences in gross
morphology between cell types were observed. After two
passages 8.7 1.0 and 7.1 2.9 PDs were observed for
chondrocytes from healthy and OA joints, respectively,
which were not signiﬁcantly different. The average PD
time was comparable for chondrocytes from healthy
(3.0 0.8 days) and OA joints (2.9 1.0 days) (n.s.).
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
After 28 days of culture, cartilaginous tissue was synthe-
sized by chondrocytes from both healthy and OA joints as
determined by the Safranin O staining and the rounded
morphology of the cells in most samples [Fig. 1(A,B)].
565Osteoarthritis and Cartilage Vol. 14, No. 6Fig. 1. Representative Safranin O stained slides of tissue synthesized, respectively, by (A) healthy chondrocytes and (B) chondrocytes from
OA joints after 28 days of culture. (C) Bern Score of the tissue synthesized after 28 days of culture supports these ﬁndings. Bars are meansþ
S.E.M. *Indicates a statistically signiﬁcant difference (P< 0.05).
566 K. G. A. Yang et al.: Chondrogenesis: chondrocytes from healthy vs OA jointsFig. 2. Collagen type I and type II immunohistochemistry of tissue synthesized by healthy and OA expanded chondrocytes after two passages
of expansion and 28 days of redifferentiation culture. (A and B) Collagen type I, (C and D) collagen type II, (A and C) tissue synthesized by
healthy chondrocytes, and (B and D) tissue synthesized by OA chondrocytes. Brown color represents positive staining.However, tissue synthesized by chondrocytes from healthy
joints showed a more hyaline cartilage-like morphological
aspect, as reﬂected by the more rounded appearance of
the chondrocytes, the lower cellularity, and the more in-
tense Safranin O staining of the matrix. These ﬁndings
were conﬁrmed by blinded histological scoring according
to the Bern grading system, as tissue synthesized by chon-
drocytes from healthy joints scored two-fold higher com-
pared to chondrocytes from OA joints (6.2 1.8 points vs
3.8 1.6 points, P¼ 0.003) [Fig. 1(C)].
All tissues stained diffusely positive for collagen type I.
Collagen type II staining was more variable between do-
nors, ranging from intense diffuse staining throughout the
whole sample to no staining, though in most samples a dif-
fuse positive staining was found. No visual differences in
immunohistochemical staining for collagen type I and type
II between chondrocytes from healthy or OA joints were
found (Fig. 2).
MATRIX TURNOVER
Final proteoglycan content after 28 days of culture was
1.4-fold higher in tissue synthesized by chondrocytes from
healthy joints compared to chondrocytes from OA joints
(P< 0.05) [Fig. 3(A)]. Upon normalization to DNA content,
no statistically signiﬁcant difference was found between do-
nor origins. Day-9 35S-incorporation normalized to DNA
content [Fig. 3(B)], average GAG release expressed as to
the total amount of GAG synthesized (sum of total GAG re-
leased and ﬁnal GAG content) [Fig. 3(C)], and total cellnumbers, as determined by DNA content [Fig. 3(D)] were
not signiﬁcantly affected by the donor tissue origin.
mRNA EXPRESSION LEVELS
Collagen type I mRNA levels were not signiﬁcantly af-
fected by donor type or passage number [Fig. 4(A)]. Colla-
gen type II mRNA levels decreased by 850-fold in
chondrocytes from OA joints between the ﬁrst and second
passages (P< 0.001). No signiﬁcant effect of donor type
on collagen type II mRNA levels was observed [Fig. 4(B)].
Independent of the passage number, the differentiation in-
dex, i.e., the collagen type II/I ratio, appeared lower in chon-
drocytes from OA joints compared to chondrocytes from
healthy joints (P¼ 0.067) [Fig. 4(C)]. Furthermore, the dif-
ferentiation index decreased signiﬁcantly between ﬁrst
and second passages for chondrocytes from both healthy
(69-fold) (P< 0.05) and OA joints (52-fold) (P< 0.001). Col-
lagen type X mRNA levels were below detection limits in
chondrocytes from healthy joints, while clearly present in
both ﬁrst and second passage chondrocytes from OA joints
of all donors (P¼ 0.008) and appeared to decrease be-
tween passages 1 and 2 (P¼ 0.073) [Fig. 5(A)]. Aggrecan
[Fig. 4(D)], cathepsin B and MMP-13 [Fig. 5(B,C)] mRNA
levels were not signiﬁcantly affected by donor tissue quality
or passage number. L-Sox-5, Sox-6 and Sox-9 mRNA
levels were not signiﬁcantly affected by the donor tissue or-
igin or the passage number, although the Sox mRNA levels
showed strikingly similar trends compared to collagen type
II mRNA levels [Fig. 6(AeC)].
567Osteoarthritis and Cartilage Vol. 14, No. 6Fig. 3. (A) Tissue GAG content after 28 days of culture. (B) Day-9 35S-incorporation normalized to DNA content. (C) Average GAG release per
total GAG synthesized during the whole culture period. (D) The DNA content after 9 and 28 days of culture. Bars are meansþ S.E.M. Statis-
tically signiﬁcant differences are indicated by * (P< 0.05).Discussion
The current study demonstrates a clear difference in carti-
lage expression patterns and chondrogenic capacity
between chondrocytes from healthy and osteoarthritic joints.
Moreover, the process of de- and redifferentiation that occurs
during in vitro chondrogenesis appears insufﬁcient to com-
pletely abolish preexisting differences between donor types.Both chondrocytes from normal and OA joints synthe-
sized cartilaginous tissue after expansion in monolayer, al-
though chondrocytes from healthy joints synthesized tissue
with signiﬁcantly better morphology, although no obvious
differences in collagen type II synthesis were observed
between donor types. The ﬁnal content of proteoglycans
in tissue synthesized by chondrocytes from normal joints
was signiﬁcantly higher compared to chondrocytes fromFig. 4. Relative mRNA levels of (A) collagen type I, (B) collagen type II, (C) the collagen type II/I ratio (differentiation index) and (D) aggrecan.
The mRNA levels shown in these graphs are relative expression levels after normalization to GAPDH as endogenous control and normaliza-
tion to the relative expression of the respective gene of interest in a control sample (mRNA extracted from OA cartilage). Bars are meansþ
S.E.M. Statistically signiﬁcant differences are indicated by * (P< 0.05).
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teoglycan synthesis rate, lower proteoglycan release rate
and higher cellularity in healthy chondrocytes may be re-
sponsible for this observation. The role of cellularity seems
supported by the fact that no signiﬁcant differences in pro-
teoglycan content per cell could be demonstrated.
No signiﬁcant effect of chondrocyte donor origin on colla-
gen type II mRNA levels was observed. Collagen type II
mRNA levels decreased signiﬁcantly between the ﬁrst and
second passages merely in chondrocytes from OA joints.
Independent of chondrocyte origin, the differentiation index
decreased signiﬁcantly between ﬁrst and second passages.
Collagen type X was only detected in chondrocytes from
OA joints and appeared to decrease between passages 1
and 2. The absence of expected statistically signiﬁcant dif-
ferences of various parameters, like the absence of increas-
ing collagen type I mRNA levels with increasing passages,
may be due to the limited number of chondrocyte donors
Fig. 5. Relative mRNA levels of (A) collagen type X, (B) cathepsin B
and (C) MMP-13 in monolayer expanded healthy and chondrocytes
from OA joints after the ﬁrst and second passages. The mRNA
levels shown in these graphs are relative expression levels after
normalization to GAPDH as endogenous control and normalization
to the relative expression of the respective gene of interest in a
control sample (mRNA extracted from OA cartilage). Bars are
meansþ S.E.M. Statistically signiﬁcant differences are indicated by
* (P< 0.05).used. All PCRs were performed in triplicate. Triplicates
were found to be very accurate. Differences in Ct-values
(¼number of cycles for PCR needed to reach a speciﬁed
threshold) within triplicates were generally less than one cy-
cle. Obvious outliers were excluded from further analysis
and therefore are not responsible for the variation in the
data. The spread in the RT-PCR data underlines that large
differences exist among different chondrocyte donors and
underlines that (especially nonsigniﬁcant) PCR data should
be interpreted with care.
However, the PCR data do demonstrate that chondro-
cytes from both healthy and OA joints increasingly dediffer-
entiate between ﬁrst and second passages, which is in
accordance with previous data showing that chondrocytes
cultured in monolayer express and synthesize decreased
amounts of collagen type II and increased amounts of colla-
gen type I with increasing passage number5,21. Despite this
trend, the differentiation index decreased to a higher extent
Fig. 6. Relative mRNA levels of (A) L-Sox-5, (B) Sox-6 and (C) Sox-
9 in monolayer expanded healthy and chondrocytes from OA joints
after the ﬁrst and second passages. The mRNA levels shown in
these graphs are relative expression levels after normalization to
GAPDH as endogenous control and normalization to the relative
expression of the respective gene of interest in a control sample
(mRNA extracted from OA cartilage). Bars are meansþ S.E.M.
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joints compared to chondrocytes from healthy joints, which
is induced by the relatively large decrease in collagen type
II expression in chondrocytes from OA joints.
Most striking were the clear differences in collagen type X
expression. This hypertrophic marker was solely expressed
by chondrocytes from OA joints and did not decrease signif-
icantly between passages 1 and 2. Surprisingly, this ten-
dency towards hypertrophy could not be explained by
decreased levels of the Sox-5, Sox-6 and Sox-9 mRNA
levels. This triad of transcription factors is known to be suf-
ﬁcient for cartilage differentiation, amongst others collagen
type II expression, and inhibits hypertrophic differentiation.
Furthermore, Sox-9 is expressed in all chondrocytes and
chondroprogenitor cells, except for hypertrophic chondrocy-
tes22e24. In contrast, in this study their levels even seem to
be increased in chondrocytes from OA joints. Collagen type
I or II, or Sox mRNA levels were studied to determine
whether differences in tissue quality could be explained
by a priori differences between chondrocyte donor types,
as these genes are required for adult chondrocyte biology.
However, no signiﬁcant differences were observed that
might explain the differences in chondrogenic capacity be-
tween healthy and OA chondrocytes. Recently, various
markers, like BMP2 and FGFR3, have been suggested to
be predictive of the chondrogenic potential of expanded
chondrocytes, while loss of chondrogenic potential of dedif-
ferentiated chondrocytes has been associated with deﬁcient
ShceErk interaction25,26. Future studies should be per-
formed to elucidate the role of these markers in the ob-
served differences in chondrogenic capacity.
The apparently diminishing differences in mRNA levels
from passages 1 to 2 and the limited differences of immuno-
histochemical and matrix turnover parameters during redif-
ferentiation culture as found in this study suggest that
differences between primary healthy and OA chondrocytes
might, at least partly, be lost during expansion in monolayer.
However, in chondrocytes from OA joints, the presence of
collagen type X mRNA after expansion, as well as the poor
morphology and lower ﬁnal proteoglycan content, suggests
that the degree of dedifferentiation induced bymonolayer ex-
pansion and the redifferentiation conditions were insufﬁcient
to abolish differences between chondrocytes from healthy
and OA joints completely. It should be noted that the differ-
ences in phenotype and chondrogenic capacity between
healthy and OA chondrocytes are, an overall property, ob-
served for a ‘‘pool’’ of cells. None of our analysis techniques
were aimed at studying differences at single cell level, while
the chondrocytes studied might actually consist of a hetero-
genic population. This hypothesis is supported by various
studies, which have demonstrated that articular cartilage
does not consist of one speciﬁc cell type, but rather contains
subpopulations of cells, which, for example, can function as
progenitor cells27e31. These results suggest that the ob-
served differences in the current study might be due to alter-
ations of small cell subsets. Furthermore, this phenomenon
might explain the discrepancies between Sox and collagen
type X mRNA levels as discussed above.
The observed differences in chondrogenic capacity could
be suggested to be attributable to the difference in average
donor age between the healthy and OA donors, as reﬂected
by differences in cell viability, cell proliferation rate and chon-
drogenic capacity. However, the proliferation rate of chondro-
cytes did not differ between donor types, which is in
accordancewith previous data failing to showa signiﬁcant ef-
fect of donor age on proliferation rate for the donor ages stud-
ied in this paper3. In addition, no differences were foundpreviously with respect to the chondrogenic capacity of
expanded chondrocytes for these age groups3. Therefore,
the observed differences are unlikely to be age-related. Fi-
nally, as both the OA and healthy chondrocytes underwent
similar number of PDs, differences with respect to the degree
of dedifferentiation resulting fromexpansionarealsounlikely.
Altogether, the difference in chondrogenic capacity be-
tween chondrocytes from healthy andOA joints is more likely
due to an a priori altered phenotype of chondrocytes fromOA
joints, leading to differences in cartilage metabolism, either
intrinsic or due to a changed sensitivity for mediators such
as growth factors. Importantly, the differences in phenotype
and chondrogenic capacity found here have several conse-
quences. Caution is warranted when using chondrocytes
from OA joints as a model for in vivo chondrogenesis, as is
done frequently both for research into basic chondrogenic
mechanisms and as a model for ACT because of the mere
availability of cartilage from these joints. This study opposes
the assumption that macroscopically less-affected cartilage
fromOA joints contains chondrocytes with identical chondro-
genic properties as chondrocytes isolated fromhealthy joints.
In fact, these chondrocytes are likely to display an intrinsically
different cartilage metabolism and/or respond differently to
applied stimuli than healthy chondrocytes as previously dis-
cussed in the concept of joint homeostasis32. However, this
statement should be put into perspective, as, currently, it is
unknownwhether changes in phenotype ofOA chondrocytes
develop as a gradual process or rather occur as a ‘‘sudden’’
alteration. Therefore, it is unclear whether chondrocytes har-
vested for ACT, which are isolated from biopsies from joints
with cartilage defects, should be considered ‘‘healthy’’.
Finally, a gradual change of a healthy chondrocyte to-
wards an OA chondrocyte may be actual in joints with trau-
matic cartilage damage, which are often seen to develop
towards OA. If this holds true, it would suggest that at
a given time point after inﬂiction of cartilage trauma, chon-
drocytes harvested from these joints for the purpose of
ACT might also be phenotypically altered and thus less suc-
cessful in healing of a cartilage defect. Further research into
the properties of cells harvested from joints with articular
trauma is required to shed light on this process, and might
provide valuable insight in the importance of timing of this
therapy.
In conclusion, in this study we demonstrated that the use
of chondrocytes harvested from joints with OA lesions leads
to altered in vitro chondrogenesis, despite the procedure in
vitro expansion and dedifferentiation postulated to level off
existing differences.
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